US7598257 — Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
Method of Use · Assigned to Incyte Corp · Expires 2027-12-24 · 2y remaining
What this patent protects
This patent protects a class of compounds that inhibit Janus kinases and are useful in treating various diseases, including immune-related diseases and cancer.
USPTO Abstract
The present invention provides heteroaryl substituted pyrrolo[2,3-b]pyridines and heteroaryl substituted pyrrolo[2,3-b]pyrimidines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.
Drugs covered by this patent
FDA Patent Use Codes
When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.
| Code | Description | Drug |
|---|---|---|
U-3228 |
— | ruxolitinib-phosphate |
U-3227 |
— | ruxolitinib-phosphate |
U-3227 |
— | ruxolitinib-phosphate |
U-3228 |
— | ruxolitinib-phosphate |
U-3228 |
— | ruxolitinib-phosphate |
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.